Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ACSS2 inhibitor MTB-9655

An orally bioavailable small molecule inhibitor of the enzyme human acetyl coenzyme A synthetase short chain family member 2 (ACSS2; acetyl CoA synthetase 2), with potential antineoplastic activity. Upon oral administration, the ACSS2 inhibitor MTB-9655 selectively targets, binds to and inhibits the activity of ACSS2. This prevents acetate metabolism to acetyl-CoA which may lead to an inhibition of tumor cell proliferation. ACSS2, an enzyme that converts acetate to acetyl-CoA, is upregulated in cancer cells in response to low nutrient availability and hypoxia. Stressed cancer cells utilize acetate as an alternative nutrient source for cell growth.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:acetyl-CoA synthetase 2 inhibitor MTB-9655
Code name:MTB 9655
MTB-9655
MTB9655
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search